Omalizumab clinical trials
Also written Xolair, IGE025 and CT-P39.
ClinicalTrials.gov finds 260 studies for Omalizumab. How that becomes 168 hereChecked on ClinicalTrials.gov
Every study that search finds has been read, apart from the 1 newest, to see whether and how it gives Omalizumab. Its counts are asked again every night. How drug pages count
- 260Found by its intervention search · See all 260 hereIt also reads titles, arm labels, keywords and descriptions, and counts the drug’s other names. Of these, 221 name it in an intervention entry. The counts it shows beside each synonym overlap: a study writing two names counts under both.
- −10
Mention it without giving it — earlier treatment, a protocol code, a title naming another drug
- Low-dose Methotrexate for Change in Global Initiative for Asthma Step 5 Medications in Chronic Severe AsthmaNCT02124226 · The search matches the record elsewhere; not givenReport a problem
- Cross-sectional Study for Identification and Description of Severe Asthma PatientsNCT02293265 · The search matches the record elsewhere; not givenReport a problem
- Omalizumab to Mepolizumab Switch Study in Severe Eosinophilic Asthma PatientsNCT02654145 · Earlier treatment, switched to mepolizumabReport a problem
- Sustained Effect of Urticaria Remission With Relatively High Dose Vitamin D Supplementation After Omalizumab DiscontinuationNCT02742805 · Stopped before vitamin D is tested; not given in the studyReport a problem
- Reslizumab in Patients With Severe Asthma Who Failed to Respond to OmalizumabNCT03074942 · Earlier treatment, not given in this studyReport a problem
- Nocturnal TLA for Severe Allergic Asthma After Withdrawal of Omalizumab TherapyNCT03480815 · Earlier treatment, withdrawn before a device is testedReport a problem
- Dupilumab for the Treatment of Chronic Spontaneous Urticaria in Patients Who Remain Symptomatic Despite the Use of H1 Antihistamine and Who Are naïve to, Intolerant of, or Incomplete Responders to Omalizumab (LIBERTY-CSU CUPID)NCT04180488 · Not given; the patients had not had itReport a problem
- Shotblocker® Use in Subcutaneous InjectionNCT04210323 · The search matches the record elsewhere; not givenReport a problem
- Dose Escalation Trial Of Safety, Pharmacokinetic/Pharmacodynamic And Preliminary Clinical Activity of Briquilimab In Adult Patients With Chronic Spontaneous Urticaria (CSU)NCT06162728 · The search matches the record elsewhere; not givenReport a problem
- Expression of TSLP Isoforms in AsthmaNCT07786870 · The search matches the record elsewhere; not givenReport a problem
- 250Give Omalizumab to participants
- −47Observe patients on it, or give it outside a trial
- −2Use it as a tool: an imaging tracer or a test of drug response
- −26Compare another treatment with it
- −7Give it beside what is tested
- 168Test it: the count on this site
Get an email when these change. Save the Omalizumab studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your alerts, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your alerts. Stop any time.
Approvals
The first approval found in each region, with its record
- United States
- 20 Jun 2003 · XOLAIR · BLA 103976 (FDA, Drugs@FDA)
- European Union
- 25 Oct 2005 · Xolair · EMEA/H/C/000606 (EMA)
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Studies by the year they started
167 studies that test it; most in 2005 (12)
| Year | Studies |
|---|---|
| 2000 | 1 |
| 2001 | 2 |
| 2002 | 3 |
| 2003 | 5 |
| 2004 | 9 |
| 2005 | 12 |
| 2006 | 12 |
| 2007 | 10 |
| 2008 | 4 |
| 2009 | 12 |
| 2010 | 6 |
| 2011 | 8 |
| 2012 | 7 |
| 2013 | 8 |
| 2014 | 12 |
| 2015 | 3 |
| 2016 | 2 |
| 2017 | 8 |
| 2018 | 4 |
| 2019 | 7 |
| 2020 | 7 |
| 2021 | 7 |
| 2022 | 6 |
| 2023 | 2 |
| 2024 | 4 |
| 2025 | 3 |
| 2026 | 3 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 62 · Other 106
Novartis Pharmaceuticals (19) · Genentech, Inc. (16) · Novartis (12) · Johns Hopkins University (11) · National Institute of Allergy and Infectious Diseases (NIAID) (7) · Stanford University (4) · Hoffmann-La Roche (4) · Creighton University (4)
Often tested with
Tested in the same studies.
Dupilumab (3) · cow's milk (1) · Fluticasone (1) · Anti-IgE antibodies (1) · Itraconazole (1) · Mepolizumab (1) · Rituximab (1)
Coming up
From the study records. Dates are the sponsors’ own estimates and often move.
Tested against it · 2 phase 3 studies under way
Omalizumab is the comparator. A study of two new drugs counts under both.
- 1Remibrutinib · Novartis Pharmaceuticals
- 1LP-003 · Longbio Pharma · next primary completion Mar 2028
Reaching primary completion within a year · 4
Studies that test Omalizumab.
- Nov 2026Effect of Omalizumab in the Skin of Food Allergy PatientsPhase 4 · National Jewish Health
- Apr 2027Omalizumab for the Treatment of Food Allergy in Patients With Elevated Total IgE LevelsPhase 2 · Johns Hopkins University
- May 2027Omalizumab Weight-Based Dosing Efficacy TrialPhase 2 · Massachusetts General Hospital
- May 2027Short Treatment with Omalizumab for Severe AsthmaPhase 4 · Assistance Publique - Hôpitaux de Paris
Studies
Open first, then newest update. How each study uses Omalizumab has had a first review, but it may not be perfect: check the study record before relying on it for anything important, and report a problem from its row. Some give it without naming it in an intervention entry: those were found by reading the record.
Testing it · 168
- Effect of Omalizumab in the Skin of Food Allergy PatientsRecruitingPhase 4National Jewish HealthNCT06618963On the skin in food allergyWritten as Omalizumab InjectionHow we knowReport a problem
- Biologics in Chronic Rhinosinusitis With Nasal PolyposisRecruitingPhase 4Medical University of South CarolinaNCT06824649One of three biologics compared in nasal polypsHow we knowReport a problem
- Oral Food Challenge After One to Two Doses of Omalizumab Treatment for Food AllergyRecruitingPhase 4Johns Hopkins UniversityNCT07845552Food challenge after one or two doses in food allergyWritten as OmalizumabHow we knowReport a problem
- Clinical Trial of Omalizumab for Allergen Sensitized and Exposed Individuals With COPDRecruitingPhase 2Johns Hopkins UniversityNCT07059091In allergen-sensitised COPDWritten as Omalizumab (Xolair®)How we knowReport a problem
- Omalizumab for the Treatment of Food Allergy in Patients With Elevated Total IgE LevelsRecruitingPhase 2Johns Hopkins UniversityNCT06934200In food allergy with high total IgEWritten as OmalizumabHow we knowReport a problem
- Omalizumab Weight-Based Dosing Efficacy TrialRecruitingPhase 2Massachusetts General HospitalNCT06943534Weight-based dosingWritten as 5mg/kg omalizumab injectionHow we knowReport a problem
- Extending Omalizumab Treatment Intervals in Patients With Chronic Spontaneous UrticariaRecruitingPhase 4Simon Francis ThomsenNCT05916937Longer dosing intervals in chronic spontaneous urticariaWritten as omalizumab 300 mg every four weeksHow we knowReport a problem
- Omalizumab Before Onset of ExacerbationsRecruitingPhase 2Children's National Research InstituteNCT05332067Before the onset of exacerbationsWritten as OmalizumabHow we knowReport a problem
- Short Treatment with Omalizumab for Severe AsthmaRecruitingPhase 4Assistance Publique - Hôpitaux de ParisNCT04763447Stopping it in severe asthmaHow we knowReport a problem
- Biologics and Sublingual ImmunotherapyNot yet recruitingPhase 4Medical University of SilesiaNCT06027073Alone and with sublingual house dust mite immunotherapyWritten as omalizumabHow we knowReport a problem
- Omalizumab to Accelerate a Symptom-driven Multi-food OITCompletedPhase 2Philippe BéginNCT04045301To speed up symptom-driven multi-food oral immunotherapyWritten as Omalizumab 16mg/kgHow we knowReport a problem
- FeNO as a Marker of Allergic Reactions to OFC and Response of OMA Treatment in Multiple FACompletedPhase 4AAADRS Clinical Research CenterNCT06437171Open label in multiple food allergy, with FeNO as a markerWritten as OmalizumabHow we knowReport a problem
- Omalizumab as Monotherapy and as Adjunct Therapy to Multi-Allergen OIT in Food Allergic ParticipantsCompletedPhase 3National Institute of Allergy and Infectious Diseases (NIAID)NCT03881696On the US labelAlone and before multi-food oral immunotherapy (OUtMATCH)Written as OmalizumabHow we knowReport a problem
- A Study of Xolair in Peanut-Allergic Subjects Previously Enrolled in Study Q2788gCompletedPhase 2Genentech, Inc.NCT00382148Extension in peanut allergyWritten as omalizumabHow we knowReport a problem
- Clinical Study Using Biologics to Improve Multi OIT Outcomes (COMBINE)CompletedPhase 2Stanford UniversityNCT03679676Alone and with dupilumab beside multi-food oral immunotherapyWritten as OmalizumabHow we knowReport a problem
- A Comparative Pharmacokinetic Study of ADL-018 Autoinjector Compared to A Pre-filled Syringe in Healthy Subjects.CompletedPhase 1Kashiv BioSciences, LLCNCT06929052The biosimilar ADL-018's auto-injector against its syringeHow we knowReport a problem
- Study of Efficacy and Safety of Omalizumab in Severe Japanese Cedar Pollinosis Adult and Adolescent PatientsCompletedPhase 3Novartis PharmaceuticalsNCT03369704In severe Japanese cedar pollinosisWritten as OmalizumabHow we knowReport a problem
- Preventing Asthma in High Risk KidsActive, not recruitingPhase 2Boston Children's HospitalNCT02570984To prevent asthma in high-risk childrenWritten as OmalizumabHow we knowReport a problem
- EValuating trEatment RESponses of Dupilumab Versus Omalizumab in Type 2 PatientsCompletedPhase 4SanofiNCT04998604Against dupilumab in type 2 asthma (EVEREST)Written as OmalizumabHow we knowReport a problem
- To Compare Efficacy and Safety of CT-P39 and EU-approved Xolair in Patients With Chronic Spontaneous UrticariaCompletedPhase 3CelltrionNCT04426890The biosimilar CT-P39 against EU Xolair in chronic spontaneous urticariaWritten as CT-P39How we knowReport a problem
See all 168 studies that test Omalizumab →
Behind its US label · 6 — the studies the FDA label of XOLAIR, OMLYCLO describes
From the Clinical Studies section of XOLAIR (2026-08), OMLYCLO (2026-08), as openFDA has it. A study the site does not hold is left out.
- Efficacy and Safety of Omalizumab in Children (6 - < 12 Years) With Moderate-severe, Inadequately Controlled Allergic AsthmaCompletedPhase 3Novartis PharmaceuticalsNCT00079937How we knowReport a problem
- A Study of the Efficacy and Safety of Omalizumab (Xolair) in Patients With Chronic Idiopathic Urticaria (CIU)/Chronic Spontaneous Urticaria (CSU) Who Remain Symptomatic Despite Antihistamine (H1) TreatmentCompletedPhase 3Genentech, Inc.NCT01287117How we knowReport a problem
- A Study to Evaluate the Efficacy, Response Duration and Safety of Xolair (Omalizumab) in Patients With Chronic Idiopathic Urticaria (CIU)/Chronic Spontaneous Urticaria (CSU) Who Remain Symptomatic Despite Antihistamine Treatment (H1)CompletedPhase 3Genentech, Inc.NCT01292473How we knowReport a problem
- A Clinical Trial of Omalizumab in Participants With Chronic Rhinosinusitus With Nasal PolypsCompletedPhase 3Hoffmann-La RocheNCT03280537How we knowReport a problem
- A Clinical Trial of Omalizumab in Participants With Chronic Rhinosinusitis With Nasal PolypsCompletedPhase 3Hoffmann-La RocheNCT03280550How we knowReport a problem
- Omalizumab as Monotherapy and as Adjunct Therapy to Multi-Allergen OIT in Food Allergic ParticipantsCompletedPhase 3National Institute of Allergy and Infectious Diseases (NIAID)NCT03881696How we knowReport a problem
Tested on its own · 130 — no other medicine in its arm
- Effect of Omalizumab in the Skin of Food Allergy PatientsRecruitingPhase 4National Jewish HealthNCT06618963On the skin in food allergyWritten as Omalizumab InjectionHow we knowReport a problem
- Oral Food Challenge After One to Two Doses of Omalizumab Treatment for Food AllergyRecruitingPhase 4Johns Hopkins UniversityNCT07845552Food challenge after one or two doses in food allergyWritten as OmalizumabHow we knowReport a problem
- Clinical Trial of Omalizumab for Allergen Sensitized and Exposed Individuals With COPDRecruitingPhase 2Johns Hopkins UniversityNCT07059091In allergen-sensitised COPDWritten as Omalizumab (Xolair®)How we knowReport a problem
- Omalizumab for the Treatment of Food Allergy in Patients With Elevated Total IgE LevelsRecruitingPhase 2Johns Hopkins UniversityNCT06934200In food allergy with high total IgEWritten as OmalizumabHow we knowReport a problem
- Extending Omalizumab Treatment Intervals in Patients With Chronic Spontaneous UrticariaRecruitingPhase 4Simon Francis ThomsenNCT05916937Longer dosing intervals in chronic spontaneous urticariaWritten as omalizumab 300 mg every four weeksHow we knowReport a problem
- Omalizumab Before Onset of ExacerbationsRecruitingPhase 2Children's National Research InstituteNCT05332067Before the onset of exacerbationsWritten as OmalizumabHow we knowReport a problem
- Biologics and Sublingual ImmunotherapyNot yet recruitingPhase 4Medical University of SilesiaNCT06027073Alone and with sublingual house dust mite immunotherapyWritten as omalizumabHow we knowReport a problem
- FeNO as a Marker of Allergic Reactions to OFC and Response of OMA Treatment in Multiple FACompletedPhase 4AAADRS Clinical Research CenterNCT06437171Open label in multiple food allergy, with FeNO as a markerWritten as OmalizumabHow we knowReport a problem
- A Study of Xolair in Peanut-Allergic Subjects Previously Enrolled in Study Q2788gCompletedPhase 2Genentech, Inc.NCT00382148Extension in peanut allergyWritten as omalizumabHow we knowReport a problem
- Study of Efficacy and Safety of Omalizumab in Severe Japanese Cedar Pollinosis Adult and Adolescent PatientsCompletedPhase 3Novartis PharmaceuticalsNCT03369704In severe Japanese cedar pollinosisWritten as OmalizumabHow we knowReport a problem
- Preventing Asthma in High Risk KidsActive, not recruitingPhase 2Boston Children's HospitalNCT02570984To prevent asthma in high-risk childrenWritten as OmalizumabHow we knowReport a problem
- To Compare Efficacy and Safety of CT-P39 and EU-approved Xolair in Patients With Chronic Spontaneous UrticariaCompletedPhase 3CelltrionNCT04426890The biosimilar CT-P39 against EU Xolair in chronic spontaneous urticariaWritten as CT-P39How we knowReport a problem
- Treatment With the Anti-IgE Monoclonal Antibody Omalizumab in Women With Asthma Undergoing Fertility Treatment. - A Proof of Concept Study.CompletedPhase 2Rigshospitalet, DenmarkNCT03727971In women with asthma having fertility treatmentWritten as Omalizumab InjectionHow we knowReport a problem
- PK, PD, Safety & Immunogenicity of ADL-018 Lyo in Healthy Adult SubjectsCompletedPhase 1Kashiv BioSciences, LLCNCT05564611The biosimilar ADL-018 against US XolairWritten as Omalizumab 150mgHow we knowReport a problem
- The Effect of Omalizumab on Allergic Rhinitis Symptoms: a Comparative StudyCompletedPhase 4Yuzuncu Yıl UniversityNCT06806826Against desloratadine in allergic rhinitisWritten as OmalizumabHow we knowReport a problem
- Molecular Endotypes of Chronic Idiopathic UrticariaActive, not recruitingPhase 4University of Colorado, DenverNCT04774315Molecular endotypes of chronic idiopathic urticariaWritten as OmalizumabHow we knowReport a problem
- Preclinical Studies of Omalizumab in Chronic Rhinosinusitis With Nasal PolyposisCompletedEarly Phase 1Johns Hopkins UniversityNCT04583501Early study in nasal polypsWritten as OmalizumabHow we knowReport a problem
- Protection From Food Induced Anaphylaxis by Reducing the Serum Level of Specific IgE (Protana).TerminatedPhase 4Carsten Bindslev-JensenNCT03964051To protect from food-induced anaphylaxisWritten as Omalizumab InjectionHow we knowReport a problem
- Behandling af Boern Med Foedevareallergi Med Omalizumab (Xolair)CompletedPhase 4Carsten Bindslev-JensenNCT04037176In children with food allergyWritten as OmalizumabHow we knowReport a problem
- To Compare the PK and Safety of Omalizumab (CT-P39, EU-approved Xolair, and US-licensed Xolair) in Healthy SubjectsCompletedPhase 1CelltrionNCT04018313The biosimilar CT-P39 against EU and US XolairWritten as CT-P39How we knowReport a problem
Showing 20 of 130. See all 130 →
Tested with established drugs · 19 — they are given beside it
- Omalizumab Weight-Based Dosing Efficacy TrialRecruitingPhase 2Massachusetts General HospitalNCT06943534Weight-based dosingWritten as 5mg/kg omalizumab injectionHow we knowReport a problem
- Short Treatment with Omalizumab for Severe AsthmaRecruitingPhase 4Assistance Publique - Hôpitaux de ParisNCT04763447Stopping it in severe asthmaHow we knowReport a problem
- Omalizumab to Accelerate a Symptom-driven Multi-food OITCompletedPhase 2Philippe BéginNCT04045301To speed up symptom-driven multi-food oral immunotherapyWritten as Omalizumab 16mg/kgHow we knowReport a problem
- A Comparative Pharmacokinetic Study of ADL-018 Autoinjector Compared to A Pre-filled Syringe in Healthy Subjects.CompletedPhase 1Kashiv BioSciences, LLCNCT06929052The biosimilar ADL-018's auto-injector against its syringeHow we knowReport a problem
- Efficacy and Safety of Zerafil® (Omalizumab) in Participants With Uncontrolled Moderate to Severe Allergic AsthmaCompletedPhase 3CinnagenNCT05813470CinnaGen's omalizumab against Xolair in allergic asthmaWritten as Omalizumab (CinnaGen)How we knowReport a problem
- Study to Assess the Efficacy and Safety of Omalizumab Treatment on ICS Reduction for Severe IgE-mediated AsthmaTerminatedPhase 4Novartis PharmaceuticalsNCT01912872To reduce inhaled steroids in severe allergic asthmaWritten as OmalizumabHow we knowReport a problem
- A Randomized, Double-Blind, Placebo-Controlled Study of Omalizumab for Idiopathic AnaphylaxisCompletedPhase 2National Institute of Allergy and Infectious Diseases (NIAID)NCT00890162In idiopathic anaphylaxisWritten as Omalizumab (Xolair)How we knowReport a problem
- Xolair (Omalizumab) for Treatment of Drug-induced Acute Tubulointerstitial Nephritis (AIN)WithdrawnPhase 2Mayo ClinicNCT01893658With prednisone in drug-induced interstitial nephritisWritten as OmalizumabHow we knowReport a problem
- A Study of Xolair (Omalizumab) in Patients With Chronic Idiopathic Urticaria (CIU) Who Remain Symptomatic With Antihistamine Treatment (H1)CompletedPhase 2Genentech, Inc.NCT00866788Dose ranging in chronic idiopathic urticaria (MYSTIQUE)Written as omalizumabHow we knowReport a problem
- Efficacy/ Safety of Omalizumab in Patients With Seasonal Allergic Asthma and Seasonal Allergic RhinoconjunctivitisCompletedPhase 3Novartis PharmaceuticalsNCT00396409With Depigoid immunotherapy in seasonal allergyWritten as OmalizumabHow we knowReport a problem
- Study to Evaluate the Effect of Omalizumab on Improving the Tolerability of Specific Immunotherapy in Patients With Persistent Allergic AsthmaCompletedPhase 4NovartisNCT00267202To make allergen immunotherapy easier to tolerateWritten as OmalizumabHow we knowReport a problem
- Omalizumab With Oral Food Immunotherapy With Food Allergies Open Label Safety Study in a Single CenterCompletedPhase 1Stanford UniversityNCT01510626With multi-food oral immunotherapyWritten as OmalizumabHow we knowReport a problem
- A Study Evaluating the Persistency of Response With or Without Xolair (Omalizumab) After Long-term TherapyCompletedPhase 4Genentech, Inc.NCT01125748Persistence of response after stopping long-term treatment (XPORT)Written as OmalizumabHow we knowReport a problem
- A Safety Study of Xolair (Omalizumab) in Patients With Chronic Idiopathic Urticaria (CIU) Who Remain Symptomatic Despite Treatment With H1 Antihistamines, H2 Blockers, and/or Leukotriene Receptor AntagonistsCompletedPhase 3Genentech, Inc.NCT01264939Safety in chronic idiopathic urticaria (GLACIAL)Written as OmalizumabHow we knowReport a problem
- Efficacy and Safety of Omalizumab in Children (6 - < 12 Years) With Moderate-severe, Inadequately Controlled Allergic AsthmaCompletedPhase 3Novartis PharmaceuticalsNCT00079937On the US labelIn children with allergic asthmaWritten as OmalizumabHow we knowReport a problem
- A Study of Omalizumab (Xolair) in Subjects With Moderate to Severe Persistent Asthma (EXTRA)CompletedPhase 3Genentech, Inc.NCT00314574In persistent asthma (EXTRA)Written as omalizumab (Xolair)How we knowReport a problem
- Efficacy and Safety of Omalizumab in Adults (18-70 Years) With Moderate to Severe Chronic UrticariaCompletedPhase 2NovartisNCT00481676In chronic urticariaWritten as Omalizumab 75-375 mgHow we knowReport a problem
- An Exploratory Study to Assess Multiple Doses of Omalizumab in Patients With Cystic Fibrosis Complicated by Acute Bronchopulmonary Aspergillosis (ABPA)TerminatedPhase 4Novartis PharmaceuticalsNCT00787917In cystic fibrosis with ABPAWritten as OmalizumabHow we knowReport a problem
- Omalizumab Use and Asthma-Related Quality of Life in Patients With Severe Persistent Allergic AsthmaCompletedPhase 4NovartisNCT00567476Added to conventional therapy, on quality of lifeWritten as OmalizumabHow we knowReport a problem
Tested in a combination · 19 — another drug in the study is under test too
- Biologics in Chronic Rhinosinusitis With Nasal PolyposisRecruitingPhase 4Medical University of South CarolinaNCT06824649One of three biologics compared in nasal polypsHow we knowReport a problem
- Omalizumab as Monotherapy and as Adjunct Therapy to Multi-Allergen OIT in Food Allergic ParticipantsCompletedPhase 3National Institute of Allergy and Infectious Diseases (NIAID)NCT03881696On the US labelAlone and before multi-food oral immunotherapy (OUtMATCH)Written as OmalizumabHow we knowReport a problem
- Clinical Study Using Biologics to Improve Multi OIT Outcomes (COMBINE)CompletedPhase 2Stanford UniversityNCT03679676Alone and with dupilumab beside multi-food oral immunotherapyWritten as OmalizumabHow we knowReport a problem
- EValuating trEatment RESponses of Dupilumab Versus Omalizumab in Type 2 PatientsCompletedPhase 4SanofiNCT04998604Against dupilumab in type 2 asthma (EVEREST)Written as OmalizumabHow we knowReport a problem
- Biosimilar Study Comparing PK, PD, Safety and Immunogencity of BP11 With US Licensed Xolair and EU Approved XolairCompletedPhase 1Syneos HealthNCT05053334The biosimilar BP11 against US and EU XolairHow we knowReport a problem
- ICS+LABA Vs. ICS+LABA+Omalizumab: Impact on Asthma Control and Gene ExpressionCompletedPhase 4Taipei Tzu Chi Hospital, Buddhist Tzu Chi Medical FoundationNCT06869382Added to ICS/LABA, on asthma control and gene expressionWritten as OmalizimabHow we knowReport a problem
- Study to Compare Efficacy Safety and Immunogenicity of ADL-018 With XOLAIR (Omalizumab) in Adults With Chronic Idiopathic UrticariaCompletedPhase 3Kashiv BioSciences, LLCNCT05774639The biosimilar ADL-018 against Xolair in chronic idiopathic urticariaWritten as Omalizumab InjectionHow we knowReport a problem
- Efficacy and Safety of Rituximab Combined With Omalizumab in Patients With Bullous PemphigoidWithdrawnPhase 3University of California, DavisNCT04128176With rituximab in bullous pemphigoidWritten as Rituximab combined with OmalizumabHow we knowReport a problem
- Study of Magnitude and Prediction of Response to Omalizumab and Mepolizumab in Adult Severe Asthma.Status unknownPhase 4Cliniques universitaires Saint-Luc- Université Catholique de LouvainNCT03476109Against mepolizumab, predicting response in severe asthmaHow we knowReport a problem
- Establishment of Precise Diagnosis and Treatment System for Refractory Chronic RhinosinusitisStatus unknownPhase 3Beijing Tongren HospitalNCT05390255With nasal steroid, one of three arms in refractory rhinosinusitisHow we knowReport a problem
- A Prospective Study on Optimizing Treatment for ABPAStatus unknownNot applicableShanghai Zhongshan HospitalNCT05129033Against itraconazole, with prednisone, in ABPAWritten as OmalizumabHow we knowReport a problem
- Comparing Treatment Efficacy With Mepolizumab and Omalizumab in Severe Asthma - "Choosebetweenamab".Status unknownPhase 4University of Newcastle, AustraliaNCT04585997Against mepolizumab in severe asthmaWritten as OmalizumabHow we knowReport a problem
- OIT and Xolair® (Omalizumab) in Cow's Milk AllergyCompletedPhase 2Hugh A Sampson, MDNCT01157117With milk oral immunotherapy in cow's milk allergyWritten as OmalizumabHow we knowReport a problem
- Treatment With Omalizumab to Improve the Asthmatic Response to Rhinovirus Experimental Infection With RhinovirusCompletedPhase 2University of VirginiaNCT02388997On the asthmatic response to rhinovirus infectionWritten as omalizumabHow we knowReport a problem
- Preventative Omalizumab or Step-up Therapy for Severe Fall ExacerbationsCompletedPhase 4National Institute of Allergy and Infectious Diseases (NIAID)NCT01430403Against an inhaled steroid boost to prevent autumn attacks (PROSE)Written as OmalizumabHow we knowReport a problem
- Effect of Intranasal Anti-IgE Antibodies on IgE ProductionCompletedNot applicableMedical University of ViennaNCT03019237Given intranasally, on IgE production in hay feverHow we knowReport a problem
- Omalizumab (Xolair) and Allergy Shots For the Treatment of Seasonal AllergiesCompletedPhase 2National Institute of Allergy and Infectious Diseases (NIAID)NCT00078195With ragweed rush immunotherapy for seasonal allergyWritten as omalizumabHow we knowReport a problem
- The Effect of Xolair ® (Omalizumab) in Mastocytosis PatientsCompletedPhase 2/3University of ZurichNCT01333293In mastocytosisHow we knowReport a problem
- Efficacy of Omalizumab in Adults (18-60 Years of Age) With Moderate-Severe, Persistent Allergic Asthma, Despite Receiving Inhaled Corticosteroids and Long Acting Beta-agonistsCompletedPhase 4Novartis PharmaceuticalsNCT00670930In persistent allergic asthma on inhaled steroidsHow we knowReport a problem
Beside an established treatment under test · 3 — an approved drug, surgery or radiation is what the study tests
Tested with Omalizumab: peanut 1
- Multi OIT to Test Immune Markers After Minimum Maintenance DoseCompletedPhase 2Andrew Long, PharmDNCT03181009In every armGiven to all; the food maintenance dose is testedWritten as OmalizumabHow we knowReport a problem
- Peanut Oral Immunotherapy and Anti-Immunoglobulin E (IgE) for Peanut AllergyCompletedPhase 1/2University of North Carolina, Chapel HillNCT00932282In every armPre-treatment in every arm; the immunotherapy's length is testedWritten as OmalizumabHow we knowReport a problem
- Multi Immunotherapy to Test Tolerance and XolairCompletedPhase 2Kari Christine NadeauNCT02626611In every armGiven to all; the food immunotherapy dose is testedWritten as OmalizumabHow we knowReport a problem
Beside a new treatment under test · 2 — a new drug, cell therapy or vaccine is what the study tests
- E-B-FAHF-2, Multi OIT and Xolair for Food AllergyCompletedPhase 2New York Medical CollegeNCT06103656With multi-food immunotherapy; an herbal formula is testedWritten as Drug: OmalizumabHow we knowReport a problem
- E-B-FAHF-2, Multi OIT and Xolair (Omalizumab) for Food AllergyStatus unknownPhase 2Xiu-Min LiNCT02879006In every armWith multi-food immunotherapy in both arms; an herbal formula is testedWritten as OmalizumabHow we knowReport a problem
Beside supportive care · 1 — a supportive treatment or test is studied
One option of several · 1 — a test or a strategy chooses among drugs
- Investigation of a Remibrutinib- and Omalizumab-based Treatment Algorithm in Adult Patients With Chronic Spontaneous Urticaria Inadequately Controlled by H1-antihistamines Within 24 WeeksRecruitingPhase 3Novartis PharmaceuticalsNCT07816328One option of a remibrutinib-based treatment algorithmWritten as OmalizumabHow we knowReport a problem
As the comparator · 26 — what is tested is compared with Omalizumab
- A Study to Evaluate the Efficacy and Safety of LP-003 Injection in Patients With Chronic Spontaneous Urticaria Who Remain Symptomatic Despite Treatment With H1 AntihistaminesNot yet recruitingPhase 3Longbio PharmaNCT07946913Written as OmalizumabHow we knowReport a problem
- A Study to Find a Suitable Dose of Exl-111 for Further ResearchRecruitingPhase 1Excellergy Inc.NCT07356713Comparator to Exl-111Written as OmalizumabHow we knowReport a problem
- Efficacy, Safety, and Pharmacokinetics of LP-003 Injection in Allergic Asthma PatientsRecruitingPhase 2Longbio PharmaNCT07342803Comparator to LP-003 in allergic asthmaWritten as OmalizumabHow we knowReport a problem
- Trial of JYB1904 in Chronic Spontaneous Urticaria.RecruitingPhase 2JemincareNCT06509334Comparator to JYB1904 in chronic spontaneous urticariaWritten as OmalizumabHow we knowReport a problem
- Efficacy and Safety of LP-003 in Patients With CSU Who Remain Symptomatic Despite Antihistamine (H1) TreatmentCompletedPhase 2Longbio PharmaNCT06228560Comparator to LP-003 in chronic spontaneous urticariaWritten as OmalizumabHow we knowReport a problem
- Phase 3b Study to Assess the Efficacy, Safety, and Tolerability of Remibrutinib in Comparison to Placebo, With Omalizumab as Active Control, in Adult CSU Patients, Followed by an Open-label 52-week Optional Extension.Active, not recruitingPhase 3Novartis PharmaceuticalsNCT06042478Active control beside remibrutinib in chronic spontaneous urticariaWritten as OmalizumabHow we knowReport a problem
- To Compare Efficacy and Safety of CMAB007 and Xolair® in Patients With Chronic Spontaneous UrticariaCompletedPhase 3Taizhou Mabtech Pharmaceutical Co.,LtdNCT06365879Reference product for the biosimilar CMAB007 in urticariaWritten as XolairHow we knowReport a problem
- Trial of JYB1904 in Patients With Allergic AsthmaCompletedPhase 2JemincareNCT06438757Comparator to JYB1904 in allergic asthmaWritten as OmalizumabHow we knowReport a problem
- Compare the PK, Safety, and Immunogenicity of Process-Changed CMAB007 and Xolair in Healthy Adult Male SubjectsCompletedPhase 1Taizhou Mabtech Pharmaceutical Co.,LtdNCT07246252Reference product for the process-changed CMAB007Written as Xolair (omalizumab)How we knowReport a problem
- Comparison of Pharmacokinetics and Safety of HS632 and Xolair® With a Single InjectionTerminatedPhase 1BioRay Pharmaceutical Co., Ltd.NCT04361812Reference product for the biosimilar HS632Written as Omalizumab (Xolair®)How we knowReport a problem
- Study to Compare Efficacy and Safety of TEV-45779 With XOLAIR (Omalizumab) in Adults With Chronic Idiopathic UrticariaCompletedPhase 3Teva Pharmaceuticals USANCT04976192Reference product for the biosimilar TEV-45779Written as XOLAIR® InjectionHow we knowReport a problem
- Study to Evaluate Tezepelumab in Adults With Chronic Spontaneous UrticariaCompletedPhase 2AmgenNCT04833855Comparator to tezepelumab in chronic spontaneous urticariaWritten as OmalizumabHow we knowReport a problem
- A Multiple Ascending Dose, Phase 1b Study of YH35324 in Atopic Healthy Subjects or Subjects With Allergic DiseasesCompletedPhase 1Yuhan CorporationNCT05564221Comparator to YH35324Written as OmalizumabHow we knowReport a problem
- A Phase III Study of and Efficacy of Ligelizumab in the Treatment of CSU in Adolescents and Adults Inadequately Controlled With H1-antihistamines.CompletedPhase 3Novartis PharmaceuticalsNCT03580356Comparator to ligelizumab (PEARL 1)Written as OmalizumabHow we knowReport a problem
- A FIH Study of YH35324 in Atopic Healthy Subjects or Subjects with Mild Allergic DiseasesCompletedPhase 1Yuhan CorporationNCT05061524Comparator to YH35324Written as OmalizumabHow we knowReport a problem
- A Single Dose, Phase 1 Study of YH35324 in Patients with Various Allergic DiseasesCompletedPhase 1Yuhan CorporationNCT05960708Comparator to YH35324Written as OmalizumabHow we knowReport a problem
- A Study of Genolair in Two Dosage Forms (Solution and Lyophilisate) and Xolair® in Healthy VolunteersCompletedPhase 1AO GENERIUMNCT06494345Reference product for GenolairHow we knowReport a problem
- A Phase III Study of Safety and Efficacy of Ligelizumab in the Treatment of CSU in Adolescents and Adults Inadequately Controlled With H1-antihistaminesCompletedPhase 3Novartis PharmaceuticalsNCT03580369Comparator to ligelizumab (PEARL 2)Written as OmalizumabHow we knowReport a problem
- To Compare the PK, PD, Safety & Immunogenicity of ADL-018 in Healthy SubjectsCompletedPhase 1Kashiv BioSciences, LLCNCT05413161Reference product for the biosimilar ADL-018How we knowReport a problem
- Study of JYB1904 (an Anti-immunoglobulin E Antibody) in Healthy Chinese SubjectsCompletedPhase 1JemincareNCT05449535Comparator to JYB1904Written as OmalizumabHow we knowReport a problem
Showing 20 of 26. See all 26 →
Observed · 47 — patients on it are followed, or it is given outside a trial
- Characteristics and Management of Patients With Severe Chronic Spontaneous and/or Inducible Urticaria Refractory to Optimized Omalizumab Treatment: A French Multicenter Observational Study.RecruitingCentre Hospitalier Universitaire de BesanconNCT07833696Urticaria refractory to it, observedHow we knowReport a problem
- T2AIR: Real-World Efficacy and Safety of Biologics Targeting Type 2 Inflammation in Asthma and COPDRecruitingShanghai Pulmonary Hospital, Shanghai, ChinaNCT07823842Real-world type 2 biologics in asthma and COPDHow we knowReport a problem
- Taiwan Severe Asthma Biologic RegistryRecruitingTaichung Veterans General HospitalNCT06456450Taiwan severe asthma biologic registryWritten as Biological Treatment for severe asthma patientsHow we knowReport a problem
- Effects of Diet and Oxidative Stress on Disease Severity and Response to Omalizumab in Chronic Spontaneous UrticariaEnrolling by invitationIstanbul Training and Research HospitalNCT07431658Diet and response in chronic spontaneous urticaria, observedHow we knowReport a problem
- ROLL'YN-OMA: an Observational Study in Patients Treated by Omlyclo®, an Omalizumab BiosimilarRecruitingCelltrion HealthCare FranceNCT07425639Patients on the biosimilar Omlyclo, observedWritten as OmalizumabHow we knowReport a problem
- Deep Phenotyping of CIndURecruitingCentre for Human Drug Research, NetherlandsNCT07359430One cohort in chronic inducible urticaria phenotypingHow we knowReport a problem
- Analysis of the Role of IgE Proteoforms in Health and DiseaseRecruitingKU LeuvenNCT07328178Some urticaria patients on it, blood studiedHow we knowReport a problem
- SKIN Disease Profiling by an Exploratory, pRospective, Biomarker Study in dermatoloGY Practice (SKINERGY)RecruitingLeiden University Medical CenterNCT07021495One treatment cohort in a skin disease biomarker studyHow we knowReport a problem
- Omalizumab for Plant-Food Allergy Due to Sensitization to LTP or ProfilinNot yet recruitingFundación Pública Andaluza para la Investigación de Málaga en Biomedicina y SaludNCT07073404In plant-food allergy, observedWritten as Omalizumab InjectionHow we knowReport a problem
- Real-life Evaluation of the Efficacy of Biologicals in Chronic Rhinosinusitis With Nasal Polyposis (CRSwNP)RecruitingUniversitaire Ziekenhuizen KU LeuvenNCT06683261Real-life biologics in nasal polyps, observedWritten as OmalizumabHow we knowReport a problem
- The Impact of Airway Allergic Diseases on Children's and Parents' Quality of LifeRecruitingWenjing ZhouNCT06535087Pre-treatment before immunotherapy in some children, observedWritten as Subcutaneous immunotherapy / Standard Treatment for Asthma and RhinitisHow we knowReport a problem
- Real Life Study of Biologicals in Patients With Severe CRSwNPRecruitingUniversity Hospital, GhentNCT05938972Real-life biologics in severe nasal polypsHow we knowReport a problem
- A Clinical Study of Omalizumab in the Treatment of Allergic Asthma(ESSENCE)RecruitingThe First Affiliated Hospital with Nanjing Medical UniversityNCT06348407Response and adherence in allergic asthma (ESSENCE), observedHow we knowReport a problem
- Phenotypic and Functional Characterization of Neutrophils and Eosinophils in Severe Asthma Treated With BiotherapyRecruitingAssistance Publique - Hôpitaux de ParisNCT05972213Blood cells in severe asthma on biologics, observedHow we knowReport a problem
- Fluctuation Analyses of Asthma Patients With Biologics UseNot yet recruitingAcademisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)NCT06024707Asthma patients on biologics, observedHow we knowReport a problem
- Spanish Academy of Dermatology and Venereology Registry of Atopic Dermatitis TherapyRecruitingFundación Academia Española de DermatologíaNCT05674695Registry of atopic dermatitis treatmentsHow we knowReport a problem
- Regulatory Post-Marketing Surveillance of Xolair® for Chronic Rhinosinusitis With Nasal PolypsCompletedNovartis PharmaceuticalsNCT05626257Post-marketing surveillance in nasal polypsHow we knowReport a problem
- BIOlogics in Severe Nasal POlyposis SurvEyActive, not recruitingUniversity Hospital, LilleNCT05228041Survey of biologics for nasal polyposisHow we knowReport a problem
- A Real-World Study of Omalizumab Treatment Patterns in Chronic Urticaria Patients in ChinaCompletedNovartis PharmaceuticalsNCT07450170Treatment patterns in chronic urticaria in China, observedHow we knowReport a problem
- Special Drug Use Observational Study of Xolair in Patients With Severe to Most Severe Seasonal Allergic Rhinitis Aged ≥ 12 Years and < 18 Years Whose Symptoms Were Inadequately Controlled Despite to Conventional TherapiesCompletedNovartis PharmaceuticalsNCT04648930Drug use survey in adolescent hay feverWritten as XolairHow we knowReport a problem
Showing 20 of 47. See all 47 →
As a tool · 2 — an imaging tracer or a test of drug response
- Impact of Increased Immunoglobulin E to Anti-herpes Simplex Virus -1 Innate Immune Responses in Atopic Dermatitis Patients With Eczema HerpeticumStatus unknownNational Jewish HealthNCT04060550Used on cells in the labWritten as XolairHow we knowReport a problem
- The Safety and Utility of Skin Testing With XOLAIR® (Omalizumab) and Placebo Omalizumab (Formulation Excipients)CompletedPhase 4Genentech, Inc.NCT00777764Used in skin testing, not as treatmentHow we knowReport a problem
What changed recently
From the registry's own updates since Oct 20, 2026.
Started recruiting1
- Oral Food Challenge After One to Two Doses of Omalizumab Treatment for Food AllergyOct 28, 2026NCT07845552
Codes
What other systems call Omalizumab · ClinicalTrials.gg INT006578
- MeSH (NLM) D000069444OmalizumabConfirmed ClinicalTrials.gov, NLM, Wikidata
- UNII (FDA) 2P471X1Z11OMALIZUMABConfirmed FDA, NLM, Wikidata
- RxNorm 302379Confirmed FDA, Wikidata
- Wikidata Q415392omalizumabConfirmed FDA, NLM, Wikidata
- NCI Thesaurus C29299OmalizumabOne source FDA
- DrugBank DB00043One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | D000069444 | Omalizumab | Confirmed ClinicalTrials.gov, NLM, Wikidata |
| UNII (FDA) | 2P471X1Z11 | OMALIZUMAB | Confirmed FDA, NLM, Wikidata |
| RxNorm | 302379 | — | Confirmed FDA, Wikidata |
| Wikidata | Q415392 | omalizumab | Confirmed FDA, NLM, Wikidata |
| NCI Thesaurus | C29299 | Omalizumab | One source FDA |
| DrugBank | DB00043 | — | One source Wikidata |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.